Research ArticleArticle
Progress Curve Mechanistic Modeling Approach for Assessing Time-Dependent Inhibition of CYP3A4
Howard J. Burt, Henry Pertinez, Carolina Säll, Claire Collins, Ruth Hyland, J. Brian Houston and Aleksandra Galetin
Drug Metabolism and Disposition September 2012, 40 (9) 1658-1667; DOI: https://doi.org/10.1124/dmd.112.046078
Howard J. Burt
Centre for Applied Pharmacokinetic Research, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, United Kingdom (H.J.B., H.P., C.S., J.B.H., A.G.); and Department of Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research and Development, Sandwich, Kent, United Kingdom (C.C., R.H.)
Henry Pertinez
Centre for Applied Pharmacokinetic Research, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, United Kingdom (H.J.B., H.P., C.S., J.B.H., A.G.); and Department of Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research and Development, Sandwich, Kent, United Kingdom (C.C., R.H.)
Carolina Säll
Centre for Applied Pharmacokinetic Research, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, United Kingdom (H.J.B., H.P., C.S., J.B.H., A.G.); and Department of Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research and Development, Sandwich, Kent, United Kingdom (C.C., R.H.)
Claire Collins
Centre for Applied Pharmacokinetic Research, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, United Kingdom (H.J.B., H.P., C.S., J.B.H., A.G.); and Department of Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research and Development, Sandwich, Kent, United Kingdom (C.C., R.H.)
Ruth Hyland
Centre for Applied Pharmacokinetic Research, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, United Kingdom (H.J.B., H.P., C.S., J.B.H., A.G.); and Department of Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research and Development, Sandwich, Kent, United Kingdom (C.C., R.H.)
J. Brian Houston
Centre for Applied Pharmacokinetic Research, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, United Kingdom (H.J.B., H.P., C.S., J.B.H., A.G.); and Department of Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research and Development, Sandwich, Kent, United Kingdom (C.C., R.H.)
Aleksandra Galetin
Centre for Applied Pharmacokinetic Research, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, United Kingdom (H.J.B., H.P., C.S., J.B.H., A.G.); and Department of Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research and Development, Sandwich, Kent, United Kingdom (C.C., R.H.)
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleArticle
PROGRESS CURVE ASSESSMENT OF TIME-DEPENDENT INHIBITION
Howard J. Burt, Henry Pertinez, Carolina Säll, Claire Collins, Ruth Hyland, J. Brian Houston and Aleksandra Galetin
Drug Metabolism and Disposition September 1, 2012, 40 (9) 1658-1667; DOI: https://doi.org/10.1124/dmd.112.046078
Research ArticleArticle
PROGRESS CURVE ASSESSMENT OF TIME-DEPENDENT INHIBITION
Howard J. Burt, Henry Pertinez, Carolina Säll, Claire Collins, Ruth Hyland, J. Brian Houston and Aleksandra Galetin
Drug Metabolism and Disposition September 1, 2012, 40 (9) 1658-1667; DOI: https://doi.org/10.1124/dmd.112.046078
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement